Quick Answer
Context Therapeutics Inc. reported Operating Income Loss of -$39.70 million for the year ending 2025.
- Context Therapeutics Inc. showed a decrease of -32.7% in Operating Income Loss from 2024 to 2025.
- This data is from Context Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: -$651.1 thousand | Q1 2021: -$840.3 thousand | Q2 2021: -$5.03 million | Q3 2021: -$1.57 million | Q1 2022: -$3.44 million | Q2 2022: -$4.01 million | Q3 2022: -$4.05 million | Q1 2023: -$6.67 million | Q2 2023: -$5.29 million | Q3 2023: -$6.18 million | Q1 2024: -$3.82 million | Q2 2024: -$3.09 million | Q3 2024: -$18.70 million | Q1 2025: -$5.53 million | Q2 2025: -$9.76 million | Q3 2025: -$10.61 million.
- Over the full 6 years of available data (2020 to 2025), Context Therapeutics Inc.'s Operating Income Loss has declined by 1,443.5%.
- Historical annual values: Fiscal year 2025: -$39.70 million | Fiscal year 2024: -$29.92 million | Fiscal year 2023: -$25.07 million | Fiscal year 2022: -$15.38 million | Fiscal year 2021: -$10.53 million | Fiscal year 2020: -$2.57 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: